
    
      Study KAN-101-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of
      KAN-101 in patients with celiac disease on a gluten free diet (GFD).

      An overview of the two parts and proposed dose groups is given below:

        1. Part A (SAD): Patients will receive a single dose of KAN-101.

        2. Part B (MAD): Patients will receive three doses of either KAN-101 or placebo.
    
  